RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight the latest findings from its pivotal Advance-HTN and Launch-HTN clinical trials. The event will focus on the efficacy and potential of lorundsrostat, the company’s investigational treatment for uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).
The webinar will feature insights from Dr. Luke Laffin, an esteemed hypertension specialist at Cleveland Clinic. Dr. Laffin will discuss the unmet medical needs in managing uHTN and rHTN, sharing his perspectives on how lorundsrostat could redefine the current treatment paradigm for patients struggling to control their blood pressure.
Event Details
- Date: Tuesday, April 1, 2025
- Time: 8:00 a.m. ET
- Dial-In Information:
- Domestic callers: 1-877-704-4453
- International callers: 1-201-389-0920
The event will also be accessible via a live webcast on Mineralys Therapeutics’ website under the “News & Events” section in the Investor Relations area.
Mineralys continues to push the boundaries of hypertension treatment, with lorundsrostat offering hope for patients who have had limited success with existing therapies. The company’s focus on developing novel solutions for this critical public health challenge underscores its commitment to improving patient outcomes worldwide.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.